Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ALK fusion ALK G1202R |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ALK fusion ALK G1202R | lung non-small cell carcinoma | sensitive | Lorlatinib | Phase I | Actionable | In a Phase I trial, treatment with Lorlatinib (PF-06463922) demonstrated safety and resulted in durable responses in patients with ALK-positive non-small cell lung cancer, including patients harboring ALK G1202R (J Clin Oncol 34, 2016 (suppl; abstr 9009)). | detail... | |
| ALK fusion ALK G1202R | lung non-small cell carcinoma | predicted - sensitive | Neladalkib | Phase Ib/II | Actionable | In a Phase I/II trial (ALKOVE-1), Nelkarmi (neladalkib) treatment resulted in an objective response rate of 68% (32/47) in patients with ALK-positive non-small cell lung cancer harboring ALK G1202R who have received prior ALK inhibitor treatments, with duration of response over 12 mo in 80% of patients (J Clin Oncol (2026) 44 (suppl_16): 8503; NCT05384626). | detail... | |
| ALK fusion ALK G1202R | lung adenocarcinoma | predicted - sensitive | Lorlatinib | Case Reports/Case Series | Actionable | In a retrospective analysis, Lorbrena (lorlatinib) treatment resulted in a partial response with a progression-free survival of 3.9 months, overall survival of 12.3 months, and a duration of treatment of 4.9 months in a patient with lung adenocarcinoma harboring an ALK fusion with ALK G1202R (PMID: 39500140). | 39500140 | |
| ALK fusion ALK G1202R | lung non-small cell carcinoma | sensitive | Lorlatinib | Guideline | Actionable | Lorbrena (lorlatinib) is included in guidelines as subsequent therapy (category 2A) for patients with advanced or metastatic non-small cell lung cancer harboring an ALK fusion with ALK G1202R (NCCN.org). | detail... |